Nan Fung Group Sells $4.3 Million Worth of Oculis Shares Amid Drug Trial Setback

Nan Fung Group Holdings Ltd sold $4.3 million in shares of clinical-stage biopharmaceutical company Oculis during Q1 2026, following the failure of its lead drug's Phase 3 trial for diabetic macular edema. The move reflects a strategic shift as Oculis pivots to other pipeline programs.

By Andy Gould, The Motley Fool Mon, June 8, 2026 at 2:16 PM GMT+3 4 min read · Yahoo Finance · June 8, 2026, 11:16 UTC

Nan Fung Group Sells $4.3 Million Worth of Oculis Shares Amid Drug Trial Setback

Tickers: $OCS

Topics: portfolio changes SEC filing stock trading

Read the full article at Yahoo Finance

More World news

Mercantile Bank Announces New Full-Service Banking Center in Holland, Michigan PR Newswire · November 12, 2026, 19:28 UTC
Broadwind Reports 48% Revenue Growth and Record Industrial Solutions Backlog in Q3 2026 Motley Fool · November 12, 2026, 19:25 UTC
MediWound Reports Q3 2026 Financial Results Amid Clinical Trial Expansion Motley Fool · November 12, 2026, 19:25 UTC
Twist Bioscience Reports Q4 2026 Revenue Growth and First Positive Adjusted EBITDA Motley Fool · November 12, 2026, 19:25 UTC
Chicago Atlantic BDC Reports Q3 2026 Growth in Net Investment Income and Record Portfolio Value Motley Fool · November 12, 2026, 19:25 UTC
Google Integrates Gemini 4 Hydrogen Model into Search to Enhance Complex Query Handling TechCrunch · November 12, 2026, 19:27 UTC
General Motors Partners with NorthStar Clean Energy for Large-Scale Solar Project in Michigan Seeking Alpha · November 12, 2026, 19:24 UTC
CNBC Select Names Accredited Debt Relief Best for Debt Resources PR Newswire · November 12, 2026, 19:25 UTC
CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Tetra Tech Forecasts FY 2027 Revenue Between $4.425B and $4.625B Amid Backlog Growth Seeking Alpha · November 12, 2026, 19:20 UTC